Polypeptide of a p53 protein-specific murin a/t-cell receptor, nucleic acids coding therefor and use thereof
OwnerThomas Stanislawski, Frank Schmitz +2inventors
InventorsThomas Stanislawski, Frank Schmitz, Holger Voss, Matthias Theobald
Life of this patent
Estimating the term…
Abstract
The invention relates to polypeptides of a murine α/β T-cell receptor mediating a p53 protein-specific T-cell response or functional variants or parts thereof or nucleic acids coding therefor, functional variants or parts thereof. Said polypeptides enable p53 protein-expressing cells to be recognized by T-cells provided with these genes, cytokines can be released, and T-cell induced lysis and/or apoptosis of tumor or leukemia cells can be performed.
Claims25
A polypeptide of a murine α/β T-cell receptor mediating a p53 protein-specific T-cell response according to SEQ ID No. 1 to SEQ ID No. 5 or functional variants or parts thereof or nucleic acids encoding this, functional variants or parts thereof.
An α- or β-chain of a T-cell receptor, which comprises the antigen recognition sequence of an antibody specific for the amino acids 264-272 of the protein p53 or of a complex of p53 264-272 and HLA-A2.
A recombinant antibody, characterized in that it comprises the antigen recognition sequence of the α- or β-chain of a T-cell receptor specific for the amino acids 264-272 of the protein p53 or of a complex of p53 264-272 and HLA-A2.
A process for the production of a medicament for the treatment of diseases associated with p53 protein, characterized in that at least one nucleic acid, at least one polypeptide, at least one host cell or at least one antibody as claimed in one of the aforementioned claims is combined, together with suitable additives and excipients.
A medicament for the treatment of diseases associated with p53 protein, characterized in that it contains at least one nucleic acid, at least one polypeptide, at least one host cell or at least one antibody as claimed in one of the aforementioned claims, if appropriate together with suitable additives and excipients.
A process for the production of a test for the discovery of functional interactors in connection with diseases associated with p53 protein, characterized in that at least one nucleic acid, at least one polypeptide or at least one antibody as claimed in one of the aforementioned claims is combined, together with suitable additives and excipients.
A test for the identification of functional interactors in connection with diseases associated with p53 protein, characterized in that it contains at least one nucleic acid, at least one polypeptide or at least one antibody as claimed in one of the aforementioned claims, if appropriate together with suitable additives and excipients.
Dependencies are inferred from the claim text.